Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2016', provides in depth analysis on Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted pipeline therapeutics. 

The report provides comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
- The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) Overview 7
Therapeutics Development 8
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Products under Development by Stage of Development 8
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Products under Development by Therapy Area 9
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Products under Development by Indication 10
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Products under Development by Companies 13
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Products under Development by Universities/Institutes 15
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics Development 23
Advaxis, Inc. 23
Aeterna Zentaris Inc. 24
Bavarian Nordic A/S 25
Curevac AG 26
GenSpera, Inc. 27
Inovio Pharmaceuticals, Inc. 28
OncBioMune Pharmaceuticals Inc. 29
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles 30
ADXS-PSA - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AEZS-120 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CV-9103 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
CV-9104 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
G-114 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
G-115 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
INO-5150 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Prostatac - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
rilimogene galvacirepvec - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Vaccine to Target PSA and HMWMAA for Prostate Cancer - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Projects 56
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products 57
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Featured News & Press Releases 58
Jul 20, 2016: Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine 58
Jul 13, 2016: OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer 58
Jun 14, 2016: OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches 59
Jun 02, 2016: Mexican Regulatory Authorities Supportive of OncBioMunes Phase 2 of ProscaVax for Prostate Cancer 59
May 18, 2016: Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer 60
May 11, 2016: OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer 61
May 04, 2016: OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer 62
Apr 28, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China 63
Apr 12, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong 63
Apr 05, 2016: Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts 64
Mar 16, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Europe 65
Feb 23, 2016: OncBioMune Continuing Phase 1 Trial, While Initiating Phase 2 Trial of ProscaVax for Prostate Cancer 65
Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On ADXS-PSA 66
Nov 10, 2015: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China and Ukraine 66
Aug 05, 2015: Advaxis's ADXS-PSA Awarded Research Grants From the Prostate Cancer Foundation and the Movember Foundation 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Advaxis, Inc., H2 2016 23
Pipeline by Aeterna Zentaris Inc., H2 2016 24
Pipeline by Bavarian Nordic A/S, H2 2016 25
Pipeline by Curevac AG, H2 2016 26
Pipeline by GenSpera, Inc., H2 2016 27
Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 28
Pipeline by OncBioMune Pharmaceuticals Inc., H2 2016 29
Dormant Projects, H2 2016 56
Discontinued Products, H2 2016 57